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Background: Hyperlysinemia is an autosomal recessive inborn error of L-lysine degradation. To date only one
causal mutation in the AASS gene encoding α-aminoadipic semialdehyde synthase has been reported. We aimed to
better define the genetic basis of hyperlysinemia.
Methods: We collected the clinical, biochemical and molecular data in a cohort of 8 hyperlysinemia patients with
distinct neurological features.
Results: We found novel causal mutations in AASS in all affected individuals, including 4 missense mutations,
2 deletions and 1 duplication. In two patients originating from one family, the hyperlysinemia was caused by a
contiguous gene deletion syndrome affecting AASS and PTPRZ1.
Conclusions: Hyperlysinemia is caused by mutations in AASS. As hyperlysinemia is generally considered a benign
metabolic variant, the more severe neurological disease course in two patients with a contiguous deletion
syndrome may be explained by the additional loss of PTPRZ1. Our findings illustrate the importance of detailed
biochemical and genetic studies in any hyperlysinemia patient.
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Hyperlysinemia is an autosomal recessive inborn error of
metabolism caused by a defect in the major catabolic
pathway of the essential amino acid L-lysine. This pathway
is primarily active in the liver and leads to the production
of acetyl-CoA (Figure 1A). In the first step, lysine and
α-ketoglutarate are converted into saccharopine by lysine-
ketoglutarate reductase (LKR, EC 1.5.1.8). Saccharopine is
then oxidized to α-aminoadipic semialdehyde and glutam-
ate by saccharopine dehydrogenase (SDH, EC 1.5.1.9). In
animals, but also other eukaryotes, both enzyme activities
are catalyzed by a single mitochondrial bifunctional en-
zyme named α-aminoadipic semialdehyde synthase [1],
which is encoded by the gene AASS. One mutation in
AASS has been reported to cause hyperlysinemia
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reproduction in any medium, provided the orHyperlysinemia is characterized by elevated plasma ly-
sine levels that exceed 600 μmol/L and can reach up to
2000 μmol/L (adult reference range 111–248 μmol/L)
[6-9]. Cases in which the plasma lysine levels are ele-
vated, but remain below 600 μmol/L, are often caused
by decreased availability of α-ketoglutarate [10], which
occurs in urea cycle disorders, pyruvate carboxylase defi-
ciency, methylmalonic aciduria and propionic aciduria.
As a consequence of the accumulating lysine, several al-
ternative biochemical reactions take place. Lysine can be
used in place of ornithine in the urea cycle resulting in
the production of homoarginine [11]. In addition, N-ε
-acetyl-L-lysine, N-α-acetyl-L-lysine and pipecolic acid
(Figure 1A) accumulate as a result of the use of alternative
or detoxifying biochemical pathways [11,12]. Hyperlysinemic
individuals may also have saccharopinuria, when the SDH
is deficient in combination with a preserved LKR activity
(also known as hyperlysinemia type 2 [13]).
Although hyperlysinemia was initially associated with
neurological damage and mental retardation, later reports
questioned this relationship. This was mainly based on a
review of 10 individuals identified with hyperlysinemia inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Molecular and biochemical studies in hyperlysinemia patients. (A) Schematic representation of the lysine degradation pathway.
Lysine can be degraded via two pathways. The pathway with L-pipecolic acid as an intermediate operates in brain and starts with oxidative
deamination. The main pathway in other organs, however, proceeds via deamination with saccharopine as an intermediate. All genes known to
operate in this pathway are indicated. ALDH7A1 is deficient in children with pyridoxine-dependent seizures [3]. GCDH is deficient in glutaric
aciduria type 1 [4]. The intermediate 2-oxoadipate is metabolized by 2-oxoadipate dehydrogenase, resembling the TCA cycle enzyme complex
2-oxoglutarate dehydrogenase. The E1 subunit of this complex is encoded by DHTKD1 and is deficient in 2-aminoadipic and 2-oxoadipic aciduria
[5]. (B) Immunoblot analysis of fibroblast homogenates of hyperlysinemia cases. Cell lysates of 2 control subjects and hyperlysinemia cases were
resolved by SDS-PAGE (30 μg of protein) blotted onto nitrocellulose and analyzed with a polyclonal antibody against AASS. (C) Relative expression
levels of AASS in fibroblasts determined using qPCR with a primer sets specific for the 50 (R) and 30 (S) part of the cDNA. Average and SD are
provided for 3 control fibroblasts. ND denotes not detectable. Expression was normalized to the level of cyclophilin B (PPIB). (D) Electropherogram
showing that the heterozygous c.460G>A mutation in patient 5 appears homozygous at the cDNA level, indicating nonsense mediated decay of
the other allele (c.2076dup).
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http://www.ojrd.com/content/8/1/57newborn screening programs (4 cases), family surveys of
a previously diagnosed case (4 cases) and during the
investigation of a boy and his family for short stature
(2 cases). Cases were rejected if the hyperlysinemia was di-
agnosed during investigation of a patient presenting with a
neurological or intellectual impairment. In none of the
identified 10 cases adverse effects could be attributed to
hyperlysinemia [14]. Furthermore, it is unclear whetherdietary restriction of lysine is beneficial [11,15], and a child
with no clinical manifestations of hyperlysinemia has been
born to an affected mother [14]. These observations indi-
cate that hyperlysinemia most likely represents a benign
metabolic variant and illustrates that the association of
nonspecific clinical signs and symptoms with biochemical
abnormalities can be coincidental. Indeed it is currently
unknown whether lysine or lysine-derived metabolites are
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duced oxidative damage to proteins and lipids, decreased
oxidized glutathione and inhibited cytosolic creatine kinase
activity [16,17]. Intrastriatal injection of lysine in rats
did not affect creatine kinase, but inhibited synaptic
Na+,K+-ATPase activity, induced lipid peroxidation and
decreased glutathione level [18]. It is currently unclear how
these findings can be related to clinical manifestations in
patients with hyperlysinemia.
Despite this, biochemical diagnoses of hyperlysinemia
are still made. Moreover, exome and whole genome se-
quencing projects are expected to identify variants in the
AASS gene of unknown significance. To better define
the genetic basis of hyperlysinemia, we collected clinical
findings, and biochemical and molecular data in a cohort
of 8 patients with distinct neurological features and
hyperlysinemia.
Methods
Collection of the cohort and case reports
The hyperlysinemia patients described here (Table 1)
were collected over the years and material was sent to a
laboratory for metabolic screening and confirmatory
testing. In most cases, patients displayed neurological
symptoms for which a metabolic cause was suspected or
had to be excluded. The studies described in this report
have been performed as part of patient care and
according to Dutch law do not need additional approval
of a medical ethical committee if used for retrospective
anonymous evaluation.
Case 1 is the first child of non-consanguineous parents.
He presented at age 6 months with psychomotor retard-
ation and failure to thrive with vomiting due to severe
gastro oesophageal reflux. In addition, there were cranio-
synostosis, microcephaly, a slightly dysmorphic face, and
early development of spastic diplegia rapidly progressing
to tetraparesis. Diagnosis of hyperlysinemia was estab-
lished following the detection of elevated pipecolic acid.
At age 4 years, motor development was severely retarded
with inability to sit or stand. At this age, treatment with
botulinum toxin was started and continued since then.Table 1 Biochemical and molecular findings in 8 cases diagno
Case Plasma lysine (μmol/L) AASS immunoblot
1 992 – 1688 Undetectable
2 787 – 1253 ND
3 1090 – 1326 Undetectable
4 868 – 1461 Undetectable
5 1554 Decreased
6 1054 – 1303 ND
7 2029 Undetectable
8 602 Undetectable
ND denotes not done.Under this treatment, the patient learned to stand up and
walk single steps with support. His expressive speech de-
velopment is also largely retarded and he communicates
with sign language. The EEG in this patient was normal as
was the brain MR imaging at an age of 4 years. He is now
8 years old and severely affected by global retardation,
spastic tetraparesis and microcephaly.
Case 2 is the younger brother of case 1 and showed a
similar but less severe clinical course. At age 2 years, he
walked on tiptoes as the first sign of a cerebral move-
ment disorder. Treatment with botulinum toxin injec-
tions was started at the age of 4 years supporting the
motor development. Currently at 7 years of age, the pa-
tient is able to walk and he can speak in full sentences.
As in his older brother, the patient was affected by fail-
ure to thrive. Both brothers were treated with a lysine
restricted diet, however, without any obvious benefit.
Case 3 is a boy of consanguineous parents (first degree
cousins). He had an epileptic event during fever at the
age of 6 months and was treated with anti-epileptic
drugs for 2 months. From the age of 3 years develop-
mental delay with spastic diplegia and behavioral distur-
bances became apparent. Magnetic resonance imaging
(MRI) of the brain was normal. At the age of 4.5 years
there was one single epileptic event without fever. A
healthy sister did not have hyperlysinemia.
Case 4 is the third child of healthy consanguineous
parents (first degree cousins). In two older healthy sib-
lings hyperlysinemia was excluded. He came to clinical
attention at the age of 10 months because of mild psy-
chomotor retardation. Screening for urinary amino acids
showed highly elevated lysine (7307 mmol/mol creatin-
ine) in the absence of saccharopinuria. On physical
examination, he displayed muscular hypotonia with brisk
tendon reflexes. An EEG was normal. The patient was
treated for three years with a strict low protein diet but
this was relaxed and eventually stopped at age 5 years
without obvious disadvantage to the neurological status.
Currently at an age of 10 years, cognition is borderline
normal with a debatable need for special education such
as speech therapy and occupational and physiotherapy.sed with hyperlysinemia
Allele 1 (coding effect) Allele 2 (coding effect)
c.194G>A (p.R65Q) c.1256T>G (p.L419R)
c.194G>A (p.R65Q) c.1256T>G (p.L419R)
c.194G>A (p.R65Q) c.194G>A (p.R65Q)
Deletion of exon 1 (no mRNA) Deletion of exon 1 (no mRNA)
c.460G>A (p.A154T) c.2076dup (p.P693SfsX10)
c.2155A>G (p.T719A) c.2155A>G (p.T719A)
Deletion of exon 20-24 Deletion of exon 20-24
Deletion of exon 20-24 Deletion of exon 20-24
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is normal.
Case 5 is the younger sister of a previously reported
affected boy [11]. Both were diagnosed with epilepsy, in-
tellectual disability and behavioral problems. The third
child in this sibship was healthy and had normal lysine
levels. The patient came to the attention of a child neur-
ologist at the age of two years because of seizures. Her
EEG was abnormal with epileptic changes. A CT at the
age of 18 showed widened ventricles. Several seizures
were observed during childhood which responded well
to standard anti-epileptic medication (valproate, carba-
mazepine). Her intelligence was low normal (IQ 86), but
she was referred to an institution because of behavioral
problems.
The patient had recurrent pneumonias as a result of
atelectasis of the left lung due to a congenital hypoplasia
of the left pulmonary artery. The left lung was surgically
removed at the age of five. The pulmonary problems
never resolved completely; at the age of 19, following in-
fluenza vaccination, she again developed a severe pneumo-
nia and as a consequence of this a chronic polyneuropathy
became manifest. Her physical inabilities at this stage ne-
cessitated admission to a rehabilitation center. After this
episode, she was lost for follow-up.
Case 6 is a boy diagnosed with intellectual and motor
disability of unknown cause. His development was im-
paired in all areas; motor development, language, and
behavior. He was hyperactive and restless, but with little
regulation. Attention deficit disorder was not excluded.
He had strabism, microcephaly, small stigmata, thin eye-
brows, a flat philtrum and a flat nose, but no syndrome
could be attributed. Prenatal exposure of the child to toxic
compounds was suspected. The child has been under the
care of the youth welfare service since birth and was
placed with foster parents before he was ten months old.
It was the intention to let the child attend a kindergarten
with special support. Urine lysine values were 2386–3196
mmol/mol creatinine. Saccharopine was noted in urine
(11.0 mmol/mol creatinine) and serum (3.5 μmol/L).
Case 7 is a boy of consanguineous parents (first degree
relatives). The first child of the parents was a healthy male.
The patient was born after an uneventful pregnancy and
delivery at 38 weeks of gestation. Birth weight and length
were normal, but head circumference was 34 cm (< 5 p).
He had no spontaneous breathing after birth and was ad-
mitted to the neonatal intensive care unit with seizures,
respiratory difficulties, hypotonia, and bradycardia at 2
days of life. Physical examination revealed a prominent
hypotonia, mild dehydration, increased deep tendon re-
flexes, absence of sucking, Moro, and grasping reflexes.
He had dysmorphic features such as microcephaly, an
underdeveloped antihelix and helix, hypotelorism and a
high arched palate. Cranial MRI showed a subacutehaemorrhage in the 4th and lateral ventricles, a mild sub-
dural haemorrhage in the occipital lobe and haemorrhages
in sinus transversus and sagittalis superior. The patient
was diagnosed with hyperlysinemia and started a special
diet containing 50 mg/kg/day lysine including 2–25 g/kg/
day protein and 140–150 kcal/kg/day energy and was
given antiepileptic drugs including phenobarbital. He had
feeding and swallowing dysfunction and was fed with a
nasogastric tube. Severe spasticity and opisthotonic pos-
turing developed in the follow up period. Unfortunately,
the patient did not respond to treatment and no improve-
ment in his signs and symptoms occurred and he died at 6
months of age.
Case 8 was born as the first child of consanguineous
parents with a birth weight of 2800 g after an uneventful
pregnancy at 38 weeks. His twin died at 3 days of life
due to pulmonary hemorrhage. He was the cousin of
case 7. Pneumonia and convulsions of generalized tonic
type manifested on the second day of life. During the fol-
low up in a local hospital for 2 months he was treated with
phenobarbital. At 16 months of age, the patient was re-
ferred to the metabolic unit. Physical examination revealed
microcephaly, an enlarged right ear, a high palate, psycho-
motor retardation, increased deep tendon reflexes, and de-
creased subcutaneous fat tissue. The patient did have head
control but could not sit with or without support. A brain
MRI was normal. His diet contained protein and calories
appropriate for his age and weight. At 4.5 years the boy
was spastic and could sit with support for a short time. He
is 13 years old now and seizures were controlled with
anticonvulsants.
Patient cell lines
Primary skin fibroblasts from patients and controls were
cultured in DMEM medium with 4.5 g/L glucose and L-
glutamine (Lonza) supplemented with 10% fetal bovine
serum (Lonza), 100 U/mL penicillin, 100 μg/mL strepto-
mycin, fungizone (Life Technologies) and 25mM Hepes
in a humidified atmosphere of 5% CO2 at 37°C.
Enzyme activity measurements
Fibroblast pellets were resuspended in PBS and homoge-
nized by sonication (twice on ice, 40J at 8W output). LKR
was assayed spectrophotometrically at 340 nm by measur-
ing the oxidation of NADPH. The reaction mixture
contained 50mM HEPES pH7.4, 10mM α-ketoglutarate,
0.3 mM NADPH and 0.25% Triton X-100. The reaction
was started with L-lysine (15mM final concentration).
SDH was assayed spectrophotometrically at 340 nm by
measuring the formation of NADH. The reaction mix-
ture contained 50mM tricine pH8.5, 5 mM NAD and
0.1% Triton X-100. The reaction was initiated by adding
saccharopine to a final concentration of 3.5 mM (stock
solution of 35 mM in 100 mM tricine, pH 8.0). Both
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centrifugal laboratory analyzer (Roche).
AASS genome sequencing and cDNA analysis
All exons, plus flanking intronic sequences of the AASS
gene (NM_005763), were sequenced after amplification
by PCR from genomic DNA. All forward and reverse
primers (Sets A to Q, Table 2) were tagged with a –
21M13 or M13rev sequence, respectively. PCR frag-
ments were sequenced in two directions using –21M13
and M13rev primers by means of BigDye Terminator
Cycle Sequencing (v1.1, Applied Biosystems, Foster City,
CA) and analyzed on an Applied Biosystems 3130xl or
3730xl DNA analyzer.
RNA was isolated from fibroblast pellets using Trizol
extraction. cDNA was synthesized by using the Super-
script II Reverse Transcriptase Kit (Invitrogen, Carlsbad,
CA, USA). Quantitative real-time PCR analysis of AASS
expression in fibroblasts was performed using the LC480
Sybr Green I Master mix (Roche) and primer sets R and
S to amplify the 50 and 30 part of the AASS cDNA, re-
spectively. In patient 1, 2 and 5 the complete AASS
cDNA was amplified and sequenced using primer sets T
and U (Table 2).
Comparative genomic hybridization
Comparative genomic hybridization (CGH) was performed
using an Agilent 180K oligo-array (Amadid 023363,
Agilent technologies Inc, Santa Clara, CA, USA) as de-
scribed before [19]. All genome coordinates mentioned
are according to human genome build 19.
Immunoblot analysis
Fibroblast homogenates were prepared in PBS using
sonication (twice on ice, 40J at 8W output). Samples
were further prepared according to the instructions for
electrophoresis of NuPAGE Bis-Tris mini gels (4–12%;
Life Technologies) using sample buffer for denaturation
and reduction of the protein disulfide bonds. Equal
amounts of protein (30 μg) were loaded. A rabbit anti-
AASS antibody (1 in 500 dilution) raised against amino
acids 528 to 649 of the protein was obtained from
Sigma-Aldrich (HPA020728). Antibodies were visualized
using IRDye 800CW or IRDye 680RD anti-rabbit sec-
ondary antibodies and the Odyssey Infrared Imaging
System (Li-Cor Biosciences).
Results and discussion
Hyperlysinemia was diagnosed based on elevated plasma
lysine levels in 8 patients with distinct neurological fea-
tures whose material was sent to a laboratory for meta-
bolic screening and confirmatory testing (Table 1). All
patients had no detectable LKR and SDH activity in fi-
broblasts. For molecular genetic analysis, we sequencedall 24 exons including the flanking exon/intron boundar-
ies of AASS by using standard Sanger sequencing tech-
niques. To determine whether the identified mutations
affect the AASS protein levels, we performed immuno-
blot analysis in fibroblast homogenates (Figure 1B).
Cases 1 and 2 are compound heterozygous for a transi-
tion c.194G>A in exon 2, and a transversion c.1256T>G in
exon 11. Both substitutions change conserved amino
acids, arginine at position 65 into glutamine (p.R65Q) and
leucine at position 419 into arginine (p.L419R). In case 3
the c.194G>A mutation was homozygous, consistent with
the reported consanguinity of the parents. Immunoblot
analysis revealed that AASS protein was absent in case 1
and 3, indicating that both mutations primarily affect pro-
tein levels (Figure 1B). In case 4 no mutations were found
in exons 2 to 24, but we failed to amplify exon 1 indicating
the presence of a deletion. Indeed, no AASS cDNA and
protein could be detected in this case (Figure 1B&C), indi-
cating that this deletion interferes with expression of
AASS. In case 5 we found two mutations, a heterozygous
transition c.460G>A in exon 4 which changes a conserved
alanine in the LKR domain into threonine (p.A154T), and
a duplication of 1 basepair c.2076dup in exon 19, which
creates a frame shift at amino acid position 693
resulting in a stop codon after 9 triplets (p.P693SfsX10).
The c.460G>A mutation appeared homozygous at the
cDNA level, indicating nonsense-mediated decay of the
c.2076dup mRNA (Figure 1D). Indeed no immunoreac-
tive protein with the predicted Mw of the truncated pro-
tein (78kDa) was observed upon immunoblotting. The
detected AASS with a Mw of 102kDa is therefore the p.
A154T mutant protein. In case 6, we found a homozygous
transition c.2155A>G in exon 19, which changes threo-
nine at position 719 into alanine (p.T719A). This mutation
affects a highly conserved amino acid in the SDH domain
of AASS. The activity of LKR is most likely at least par-
tially conserved, which is evidenced by the fact that this
patient displayed hyperlysinemia and saccharopinuria. Un-
fortunately, the available lymphoblasts of this patient were
not suited for follow up analysis, because AASS activity
and protein are undetectable in this cell type.
In cases 7 and 8 no mutations were found in exons 1
to 19, but we failed to amplify exon 20–24 indicating the
presence of a large deletion. Despite the fact that the 50
part of the AASS cDNA could be detected (Figure 1C),
no AASS protein was present in both cases (Figure 1B).
In order to determine the size of this deletion, we
performed CGH in case 7. This analysis revealed a
homozygous deletion of 126kb at 7q31.32 (karyotype
arr7q31.32(121590497–121716631)x0) involving two
genes, AASS and PTPRZ1. Although not exactly known,
the deletion breakpoint for AASS must be located in in-
tron 19 or exon 20. PTPRZ1 or protein tyrosine phos-
phatase, receptor-type, Z polypeptide 1 is encoded by 30
Table 2 Primer sets used for AASS mutation analysis
Amplicon Sequence (50>30)1 Exons Regions of cDNA
A [−21M13]-cgattggcagatgagaaggt 1 (c.–221-c.–16)
[M13-Rev]-atctccaccgcatctcacag
B [−21M13]-cacttgacatcccagttttcc 2 (c.–15-c.210)
[M13-Rev]-ttcctcagctggagtaagca
C [−21M13]-tgttgtgcctttgctacaca 3 (c.211-c.387)
[M13-Rev]-tcccatctgaaaaacaaggtag
D [−21M13]-ttgctacctggcgttttctaa 4 (c.388-c.472)
[M13-Rev]-cttgccgcagaaaagagaaa
E [−21M13]-catgcagattggagaacgag 5 & 6 (c.473-c.687)
[M13-Rev]-atggctgcccacatcatt
F [−21M13]-ggaaggcaagtggagctatg 7 & 8 (c.688-c.894)
[M13-Rev]-tgggcacatgtagacctgaa
G [−21M13]-tttcttcggcatgcaataca 9 (c.895-c.1043)
[M13-Rev]-ctgccaagaggtcaagaaaga
H [−21M13]-gcagagtcctgaagaatgagc 10 & 11 (c.1044-c.1278)
[M13-Rev]-ccccaagagacaagtaagcag
Internal rev seq primer cagcaacccatctcacat
I [−21M13]-gggcagagttgattgcttgt 12 & 13 (c.1279-c.1406)
[M13-Rev]-gccagccacttagtttggat
J [−21M13]-ttgtggaatgcaagattctg 14 & 15 (c.1407-c.1655)
[M13-Rev]-tgatttgtgcaccttctgga
Internal rev seq primer cagaaacaaagtagtcttc
K [−21M13]-gagtgcctgtgtctttttgg 16 & 17 (c.1656-c.1875)
[M13-Rev]-gaacctgggagatggaggtt
Internal forw seq primer ctgagtggatccatggcattg
L [−21M13]-tcaaatggtacatgctttgaaga 18 (c.1876-c.2016)
[M13-Rev]-gggtttgggatcagggagta
M [−21M13]-ttctgttgctttctttgttcg 19 (c.2017-c.2184)
[M13-Rev]-caatcaatcataagattcctgaaaaa
N [−21M13]-gacaggaaaacctgctaggc 20 (c.2185-c.2280)
[M13-Rev]-gactcccatcactgggtcac
O [−21M13]-ttgaggtgtatttgaagttcagtg 21 & 22 (c.2281-c.2485)
[M13-Rev]-acatcttcccattcctgctg
Internal rev seq primer ctacccacattagagcaacg
P [−21M13]-ggcaggaggagatgacagac 23 (c.2486-c.2662)
[M13-Rev]-actcagccaccttggaactg
Q [−21M13]-aaaatgcctaggcctccaag 24 (c.2663-c.*187)
[M13-Rev]-gtggcttgcatctcctgttc
R 50-tctccaagggtcttcaccac-30 c.47-c.66
50-agaatgccaccagctttgac-30 c.236-c.217
S 50-agttcctcaggcagagtcca-30 c.2421-c.2440
50-ggctgaaaagccattgatgt-30 c.2607-c.2588
T 50-gccttccatcccagtttctt-30 c.–116-c.–97
50-ctgcatctctcaccacagga-30 c.1323-c.1342
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Table 2 Primer sets used for AASS mutation analysis (Continued)
Internal seq. primer 50-tgcatttttctcccacacaa-30 c.318-c.337
Internal seq. primer 50-cccaaactggagacctcaga-30 c.755-c.774
U 50-gaatgctttggagacatgctt-30 c.1237-c.1257
50-ggtgtattgcctgggaagaa-30 c.*23-c.*42
Internal seq. primer 50-ctgcaagctacatcacaccag-30 c.1724-c.1744
Internal seq. primer 50-tggcatttcttctgctcaca-30 c.2136-c.2155
1All forward and reverse primers were tagged with a –21M13 (50-TGTAAAACGACGGCCAGT-30) sequence or M13rev (50-CAGGAAACAGCTATGACC-30) sequence.
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in exon 2 or intron 2, which will prevent the expression of
functional PTPRZ1. PTPRZ1 is a protein tyrosine phos-
phatase, which is mainly expressed in the developing and
mature brain (astrocytes, oligodendrocyte precursors,
immature and mature oligodendrocytes). Binding with a
variety of cell adhesion and matrix molecules affect intra-
cellular phosphatase activity [20,21]. Although PTPRZ1
knockout mice have no gross anatomical alterations in
their nervous system or other organs, they do display dis-
turbed motor coordination and nociception and have de-
creased recovery from demyelinating lesions [22,23].
Thus the physiological role of PTPRZ1 may be in
oligodendrogenesis, promotion of neurite outgrowth and
glial adhesion [21]. Our data indicate that cases 7 and 8
have a novel contiguous gene deletion syndrome that
was biochemically diagnosed as hyperlysinemia. We
speculate that the severe neurological disease in these
cases is caused by a loss of PTPRZ1 function.
In addition to the single mutation reported before, we
now describe 7 novel mutations, one of which was
present in two unrelated patients (p.R65Q). All missense
mutations affect conserved amino acids and are not
present in the SNP or 1000 genomes database. The
causal nature of these mutations is further evidenced by
deficient LKR and SDH activities in all patients’ fibro-
blasts and the undetectable AASS protein levels in all
but one case. In our cohort of patients, hyperlysinemia
tracks with distinct neurological features. This could re-
flect the selection bias in our cohort, since amino acid
analyses are mainly performed in patients with neuro-
logical abnormalities. Although, the neurological pheno-
type segregated with the biochemical abnormalities in all
studied siblings, this is only weak evidence for causality
in recessive disorders with single cases and consanguin-
ity. In addition, there is a broad range of clinical pheno-
types in the group of patients in which only AASS is
defective. Patient 1 and 2 are more severely affected than
patient 3 and 4, despite the fact that all cases appear to
have no functional AASS protein. We suggest that the
pathophysiology of AASS deficiency may be better
addressed in a model organism such as an Aass knockout
mouse. Population-based studies in which the prevalenceof hyperlysinemia is measured (through metabolomics)
in conjunction with genotyping and clinical phenotyping
might provide additional insight.
Conclusions
We conclude that in our cohort of 8 cases, hyperlysinemia
is caused by mutations in the AASS gene. In two patients
originating from one family, the hyperlysinemia was
caused by a contiguous gene deletion syndrome affecting
AASS and PTPRZ1. Our findings illustrate the importance
of detailed biochemical and genetic studies in any
hyperlysinemia patient.
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